The Rutgers Cancer Institute of New Jersey announced it has begun a clinical trial that will examine whether an anti-malaria drug doctors are administering as an off-label use to treat the coronavirus is more effective when taken with an antibiotic. Clinical trials take year to complete. But Rutgers, a nationally recognized comprehensive cancer center, has the in-house expertise to move faster, said Rutgers Cancer Institute Director Steven K. Libutti, who is overseeing the trial. To read the full article.
Recent Posts
- Consider the potential harms of antibiotics. Lives may depend on it.
- Which cancer causes the most NJ deaths — and why are more Black residents dying of it?
- Bracing for the Dr. Oz effect on health care.
- Rutgers Health Earns National Honor for Advancing Inclusive Excellence.
- Study Reveals How Cell Types Shape Human Brain Networks.
Categories
- Community (2,092)
- Covid (979)
- CTO Events (5)
- News (2,655)
- Pilots (20)